A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Subjects will be asked to participate in this clinical trial to examine the safety of
2-deoxyglucose (an agent which is quite similar to glucose) in the treatment of solid tumors
and hormone refractory prostate cancer. This agent works by blocking the metabolism of
glucose in the cells of the body. Although all cells require glucose for metabolism, it is
believed that cancer cells require significantly more glucose than normal cells to grow.
Therefore, even slight effects of glucose metabolism in cancer cells might result in the
shrinkage of certain cancers. This agent has been given to humans before and has only caused
mild nausea, vomiting and glucopenia (low blood sugar) at the doses given in these studies.
This study will further examine the safety of 2-deoxyglucose in the treatment of advanced
solid tumors and hormone refractory prostate cancer. The information obtained in this study
will be used to design future clinical studies with 2-deoxyglucose. Subjects will be asked to
take an oral solution of 2-deoxyglucose daily, by mouth, while on this study. They will be
asked to have CT Scans, Bone Scans, and optional PET (Positron Emission Tomography) Scans
prior to starting this study. PET scans will also be performed shortly after the start of the
study and after 2 cycles (6 weeks) of therapy. Subjects will be asked to have a comprehensive
physical examination and blood work prior to the start of the study. During the first 2
cycles of the study subjects will be asked to have blood drawn at different time intervals
for the first 2 days of each cycle. While on the study, they will be asked to return to the
clinic at intervals of 1 week for a physical examination and blood tests. Subjects will also
be asked to have CT Scans and Bone Scans at intervals of 9 weeks while on the study.